Faruqi & Faruqi Investigates Significant Stock Losses for Tvardi Therapeutics Investors

Investigation into Tvardi Therapeutics

Faruqi & Faruqi, LLP, a national leader in securities law based in the United States, has embarked on an investigation concerning potential legal claims on behalf of investors affected by significant financial losses in Tvardi Therapeutics, Inc. (NASDAQ: TVRD). This comes after a notable plunge of over 80% in Tvardi's stock price, triggered by disappointing results from their clinical trial.

Background of the Investigation

Tvardi Therapeutics had been conducting a Phase 2 clinical trial for its treatment candidate, TTI-101, targeted at idiopathic pulmonary fibrosis. The trial was aimed at assessing the safety and efficacy of TTI-101, focusing on pharmacokinetics and preliminary outcomes related to lung function. However, on October 13, 2025, preliminary data revealed that the study had not met its objectives, leading to a swift decrease in stock value that raised concerns among investors.

According to the reports, while the baseline characteristics of the patients were comparably similar across various treatment groups, the placebo-treated participants exhibited significantly lower changes in the Forced Vital Capacity (FVC) than those treated with TTI-101. This raised alarms regarding the efficacy of the treatment and has cast doubts on the potential for future success.

Investor Action

James (Josh) Wilson, a partner at Faruqi & Faruqi, emphasized the importance of investors seeking clarity on their legal rights in light of these developments. He encourages anyone who has suffered considerable losses while holding Tvardi stock or options to reach out for a free consultation to discuss their options moving forward. With millions of dollars recovered for investors in the past, the firm is positioned to provide guidance and help rally investor interests in the current situation.

For more information, those affected can visit Faruqi & Faruqi’s website dedicated to Tvardi at www.faruqilaw.com/TVRD or call directly to communicate how their financial situation may qualify for further legal action.

Importance of Prompt Action

Faruqi & Faruqi's proactive approach highlights the significance of quickly addressing potential losses. Waiting too long to initiate legal action may impede an investor's ability to recover losses, making it imperative to act promptly. The firm assures confidentiality in all discussions with clients, providing a secure platform to explore potential remedial steps in securing financial compensation.

With the securities field constantly evolving, investors are encouraged to remain vigilant about the companies they support and the legal standing of their investments. As Tvardi attempts to navigate the aftermath of its trial results, the role of legal advocacy becomes ever more critical in protecting investors’ rights and interests.

Faruqi & Faruqi remains committed to transparency and investor education, fostering informed decisions in an often unpredictable market. Investigating claims against Tvardi is just one of many initiatives the firm spearheads to safeguard investors, ensuring that every client's voice is heard and considered in the wake of such unsettling market turmoil.